1. Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients.
- Author
-
Clarke CL, Kushi LH, Chubak J, Pawloski PA, Bulkley JE, Epstein MM, Burnett-Hartman AN, Powell B, Pearce CL, and Spencer Feigelson H
- Subjects
- Adolescent, Adult, Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, California epidemiology, Colorado epidemiology, Comorbidity, Cystadenocarcinoma, Serous drug therapy, Cystadenocarcinoma, Serous pathology, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Grading, Neoplasm Staging, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Prognosis, Retrospective Studies, Survival Rate, Washington epidemiology, Young Adult, Cancer Survivors statistics & numerical data, Cystadenocarcinoma, Serous mortality, Ovarian Neoplasms mortality
- Abstract
Background: Relatively little is known about factors associated with long-term survival (LTS) following a diagnosis of ovarian cancer., Methods: We conducted a retrospective study of high-grade serous ovarian cancer (HGSOC) to explore predictors of LTS (defined as ≥7 years of survival) using electronic medical record data from a network of integrated health care systems. Multivariable logistic regression with forward selection was used to compare characteristics of women who survived ≥7 years after diagnosis ( n = 148) to those who died within 7 years of diagnosis ( n = 494)., Results: Our final model included study site, age, stage at diagnosis, CA-125, comorbidity score, receipt of chemotherapy, BMI, and four separate comorbid conditions: weight loss, depression, hypothyroidism, and liver disease. Of these, only younger age, lower stage, and depression were statistically significantly associated with LTS., Conclusions: We did not identify any new characteristics associated with HGSOC survival., Impact: Prognosis of ovarian cancer generally remains poor. Large, pooled studies of ovarian cancer are needed to identify characteristics that may improve survival., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF